GlassScriptPhysician profile
Arman Murabia
NPI 1639557770
$1,257.94
in general payments reported to CMS, 2019-2025
17 companies · $535 in 2025
The $535 reported for 2025 was more than what 90% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $287 · 2020: $47.71 · 2022: $165 · 2024: $223 · 2025: $535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $758.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $758.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $252.54 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $209.75 | 2019-2020 | |
| Glaxosmithkline, LLC. | $142.80 | 2024-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Jazz Pharmaceuticals INC. | $99.99 | 2022 | |
| Electromed, INC. | $87.51 | 2025 | Smartvest |
| Regeneron Healthcare Solutions, INC. | $83.12 | 2019-2024 | Dupixent |
| Harmony Biosciences LLC | $49.74 | 2024-2025 | |
| Avadel Cns Pharmaceuticals, LLC | $44.73 | 2025 | Lumryz |
| Inspire Medical Systems, INC. | $41.05 | 2024 | Inspire |
| Takeda Pharmaceuticals U.S.A., INC. | $37.16 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $33.49 | 2019-2020 | |
| 3b Medical, INC. | $31.51 | 2025 | Luna |
| Lilly USA, LLC | $31.22 | 2025 | Zepbound, Mounjaro |
| Amgen INC. | $29.29 | 2025 | Tezspire |
| Insmed, INC. | $28.76 | 2025 | Arikayce |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $28.69 | 2024 | Yupelri |
| Baxter Healthcare | $26.59 | 2025 | Hillrom - Monarch Airway Clearance System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arman Murabia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.